The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Immunizations “are not all good or bad,” says the chair of the overhauled panel.

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

Kennedy’s decision to replace ACIP wholesale and the comments he has made about deviating from standard vaccine policymaking ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...